BMS Presents Two-Year Results of Deucravacitinib in P-III (POETYK PSO) LTE Trial for the Treatment of Plaque Psoriasis at EADV 2022
Shots:
- The P-III (POETYK PSO) LTE trial evaluates deucravacitinib (6mg, qd) in 1221 patients with PsO. Enrolled patients were received 1 dose of deucravacitinib
- The results showed the durable efficacy & consistent safety profile with that observed in prior P-III (POETYK PSO-1 & 2) trials, clinical efficacy was maintained through ~2yrs. with response rates for PASI 75 & sPGA 0/1 (77.7% & 58.7%) @60wk., treatment discontinuation due to SAEs & AEs remained low for ~2yrs. with no safety signals
- Deucravacitinib is the 1st selective allosteric TYK2 inhibitor & is currently under regulatory review in multiple regions including the US, EU & Japan for PsO & under MHRA for PsO, pustular psoriasis & EP
Ref: Businesswire | Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
